Opioid Agonist Treatment Dispensing Trends Between 2018 and 2022 Across Six Canadian Provinces
Canadian Journal of Physiology and Pharmacology · 2026
DOI: 10.1139/cjpp-2025-0171 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2026. Verfasst von Ria Garg und 12 weiteren Autor:innen. Beteiligte Einrichtung: ICES, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Analgesics, Opioid, Buprenorphine, Opiate Substitution Treatment.
Abstract (Originalsprache)
Opioid agonist treatment (OAT) is the recommended first-line therapy for individuals with opioid use disorder. The availability of different products and prescribing guidance for OAT has rapidly evolved in recent years. Therefore, we conducted a repeated cross-sectional study using pharmacy dispensing data from six Canadian provinces to examine trends in methadone and buprenorphine use between January 2018 and December 2022. Monthly population-adjusted rates of OAT recipients were calculated by province, and annual cohorts were stratified by demographic characteristics and OAT type. OAT prevalence varied across provinces, ranging from 1.03 per 1,000 in Quebec to 3.59 per 1,000 in British Columbia. Increases in OAT use between 2018 and 2022 were observed in Alberta (3.00 to 3.75 per 1,000) and Manitoba (1.68 to 2.39 per 1,000), while rates remained relatively stable elsewhere. OAT use was highest among adults aged 25–44 years, males, and residents of lower-income neighbourhoods. A notable shift toward buprenorphine prescribing was observed across all provinces, with 45% to 74% of OAT recipients dispensed a buprenorphine product in 2022. These cross-provincial differences in OAT rates likely reflect variations in opioid use disorder prevalence, prescribing practices, and access to care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ICES, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
- Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St., Toronto, ON M5S 3M2, Canada.
- Li Ka Shing Knowledge Institute, St. Michael's Hospital, 209 Victoria St., Toronto, ON M5B 1T8, Canada.
- Canadian Institute for Health Information, 4110 Yonge Street Suite 300, Toronto, ON M2P 2B7, Canada.
- School of Public Health, University of Alberta, 11405 87 Ave NW, Edmonton, AB T6G 1C9, Canada.
- Institut National d'Excellence en Santé et en Services Sociaux (INESSS), 2021 Avenue Union, Montréal, QC H3A 2S9, Canada.
ORCID-Profile: Tara Gomes
Zitieren
APA
Garg, R., Hamzat, B., Cheung, G., Eurich, D., Kaboré, J., de Léséleuc, L., Liu, Z., Missaoui, H., Randall, J., Shearer, D., Stock, D., Yang, J., & Gomes, T. (2026). Opioid Agonist Treatment Dispensing Trends Between 2018 and 2022 Across Six Canadian Provinces. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2025-0171
Vancouver
Garg R, Hamzat B, Cheung G, Eurich D, Kaboré J, de Léséleuc L, et al. Opioid Agonist Treatment Dispensing Trends Between 2018 and 2022 Across Six Canadian Provinces. Canadian Journal of Physiology and Pharmacology. 2026. doi:10.1139/cjpp-2025-0171
BibTeX
@article{Garg2026,
author = {Garg, Ria and Hamzat, Bisola and Cheung, Grace and Eurich, Dean and Kaboré, Jean-Luc and de Léséleuc, Louis and Liu, Zhaoyu and Missaoui, Houssem and Randall, Jason R and Shearer, Dana and Stock, David and Yang, Joanna and Gomes, Tara},
title = {Opioid Agonist Treatment Dispensing Trends Between 2018 and 2022 Across Six Canadian Provinces},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2026},
doi = {10.1139/cjpp-2025-0171}
}
EUVIMED